Pharming Group N.V. (PHAR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Pharming Group N.V. (PHAR) closed at USD 9.64 on 2026-10-14, a change of -29.9 % over the past year, with a market capitalization of USD 681.59M.

Pharming Group N.V. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Pharming Group N.V. key figures

Previous close

USD 9.64 (2026-10-14)

1-year change

-29.9 %

Market cap

USD 681.59M

Enterprise value

USD 636.61M

P/E ratio (trailing)

74.08

P/E ratio (forward)

31.37

EPS (trailing)

0.13

EPS (forward)

0.31

PEG ratio

n/a

Price to book

2.52

Revenue growth

-3.2 %

Earnings growth

-62.9 %

Dividend per share (trailing)

0.00

Short ratio

0.57

Employees

407

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Pharming Group N.V.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Pharming Group N.V. and compare it with other stocks.